Cash from Investing (Quarterly) Chart

Historical Cash from Investing (Quarterly) Data

View and export this data back to 2010. Start Trial.
Date Value
June 30, 2026 -0.5769M
March 31, 2026 -1.692M
December 31, 2025 -1.019M
September 30, 2025 -1.032M
June 30, 2025 -2.648M
March 31, 2025 -0.006M
December 31, 2024 -0.0014M
September 30, 2024 -0.0126M
June 30, 2024 0.0018M
March 31, 2024 -0.108M
December 31, 2023 -0.0986M
September 30, 2023 -1.120M
June 30, 2023 -24.43M
March 31, 2023 -3.799M
December 31, 2022 -5.031M
September 30, 2022 -8.754M
June 30, 2022 -13.70M
March 31, 2022 -20.22M
December 31, 2021 -25.42M
September 30, 2021 -7.662M
June 30, 2021 -1.424M
March 31, 2021 -0.505M
December 31, 2020 -4.716M
September 30, 2020 -4.163M
June 30, 2020 -0.014M
Date Value
March 31, 2020 0.00
December 31, 2019 -0.005M
September 30, 2019 -0.0021M
June 30, 2019 -0.003M
March 31, 2019 -0.007M
December 31, 2018 0.001M
September 30, 2018 -0.003M
June 30, 2018 -0.0019M
March 31, 2018 -0.002M
December 31, 2017 -0.0233M
September 30, 2017 -0.0706M
June 30, 2017 2.549M
March 31, 2017 4.694M
December 31, 2016 3.901M
September 30, 2016 5.241M
June 30, 2016 2.734M
March 31, 2016 4.718M
December 31, 2015 -1.925M
September 30, 2015 -22.09M
June 30, 2015 -0.153M
March 31, 2015 0.00
December 31, 2014 -0.125M
September 30, 2014 -0.16M
June 30, 2014 -0.105M
March 31, 2014 -0.002M

Cash From Investing Definition

Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.

Read full definition.

Cash from Investing (Quarterly) Range, Past 5 Years

View Cash from Investing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Investing (Quarterly) Benchmarks

View Cash from Investing (Quarterly) Benchmarks
Start Trial
Inovio Pharmaceuticals, Inc. 6.147M
Nektar Therapeutics -399.11M
Heron Therapeutics, Inc. -3.265M
ACADIA Pharmaceuticals, Inc. -8.529M
Alnylam Pharmaceuticals, Inc. -363.46M